[go: up one dir, main page]

DE835928C - Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect - Google Patents

Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect

Info

Publication number
DE835928C
DE835928C DEK1647A DEK0001647A DE835928C DE 835928 C DE835928 C DE 835928C DE K1647 A DEK1647 A DE K1647A DE K0001647 A DEK0001647 A DE K0001647A DE 835928 C DE835928 C DE 835928C
Authority
DE
Germany
Prior art keywords
salicylate
methylheptane
methylamino
dimethylaminophenyldimethylpyrazolone
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DEK1647A
Other languages
German (de)
Inventor
Dr Heinrich Boie
Dr Karl Wulzinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Priority to DEK1647A priority Critical patent/DE835928C/en
Application granted granted Critical
Publication of DE835928C publication Critical patent/DE835928C/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Verfahren zur Herstellung von analgetisch wirkenden konzentrierten wäßrigen Lösungen des 6-Methylamino-2-methylheptansalicylats 1a @lirde sctio@n v orgesclila,gen, das Analgeticum I)irncthvlaminophenvldiinethylpyrazolon mit Salzen des @letliylamino-6-methvl-2-hel)ten-2 als Spasmoly- ticum zu Doppelverbindungen zu vereinigen. Nach einem anderen Vorschlag wird das schwer lösliche NIetliy,laminoniethvlhelitensalic@-lat dadurch in kon- zentrierte wä ßrige Lösung gebracht, daß man es mit löslichen Salzen aromatischer `fonocarbonsäuren oder löslichen Doppelverbindungen dieser Salze, wie z. B. Dimethylaminophenvldimetliylpyrazolon - Calcium- salicvlat, als Lösungsvermittler vereinigt. Das ebenfalls spasmolytisch wirkende 6-Methyl- arnino-2-metlivllieptansalicylät hat vor dem vor- genannten entsprechenden -hel>teiisalicylat den Vor- teil, daß cs ähnlich stark spasmolytisch wirksam ist und bei seiner #vritlietischen Gewinnung keinerlei Schwierigkeiten bereitet. Seiner unmittelbaren Ver- wendung zur Herstellung analgetisch wirkender wäß- riger Lösungen in Kombination mit Dimethylamino- phenyIdirnethylpyrazolon steht jedoch die Tatsache entgegen, daß aus diesen beiden Komponenten auch mit überschüssigem Dimethylaminophenyldimethyl- pyrazolon nur solche wäß ige Lösungen hergestellt werden können, die weniger als 6°/o und mehr als 25°/o bfethylaminomethylhepiansalicylat enthalten, während bei Ansätzen in dem dazwischenliegenden Bereich von 6 bis 25°/a Methylaminomethylheptan- salicylat sich zwei übereinanderstehende Schichten ausbilden. Dadurch fehlt für klar bleibende Lösungen gerade jener Konzentrationsbereich für die spasmo- lytische Komponente, der für die therapeutischen Zwecke erforderlich ist und der nach dem früheren Vorschlag mit Methylaminomethylheptensalicylat verfügbar ist. Auch bei Anwendung der Doppelverbindung Dimethylaminophenyldimethylpyrazolon-Calciunisalicylat als Lösungsvermittler für Methylaminomethylheptansalicylat werden nicht in allen Konzentrationen einheitliche Lösungen erhalten.Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect 1a @lirde sctio @ nv orgesclila, gen, the analgesic I) irncthvlaminophenvldiinethylpyrazolon with salts des @ letliylamino-6-methvl-2-hel) ten-2 as Spasmoly- ticum to unite to double connections. To another suggestion will be that which is difficult to dissolve NIetliy, laminoniethvlhelitensalic @ -lat thereby in con- centered aqueous solution that you can put it with soluble salts of aromatic `phonocarboxylic acids or soluble double compounds of these salts, such as. B. Dimethylaminophenvldimetliylpyrazolon - Calcium- salicvlat, united as a solubilizer. The spasmolytic 6-methyl- arnino-2-metlivllieptansalicylät has before the named corresponding -hel> teiisalicylat precedes part that cs has a similarly strong spasmolytic effect and in its #vritlietic acquisition none Causes difficulties. His immediate relationship application for the production of analgesic water solutions in combination with dimethylamino- phenyIdirnethylpyrazolon, however, faces the fact contrary to that from these two components too with excess dimethylaminophenyldimethyl- Pyrazolon only produced such aqueous solutions may be less than 6 ° / o and more than Contain 25 ° / o methylaminomethylhepian salicylate, while with approaches in the intermediate one Range from 6 to 25 ° / a methylaminomethylheptane salicylate two superimposed layers form. As a result, there is a lack of clear solutions precisely that concentration range for the spasmo- lytic component necessary for the therapeutic Purposes is required and that after the earlier Suggestion with methylaminomethylheptensalicylate is available. Even when using the double compound dimethylaminophenyldimethylpyrazolone calcium salicylate as a solubilizer for methylaminomethylheptane salicylate, uniform solutions are not obtained in all concentrations.

Es wurde nun gefunden, daß klar bleibende Lösungen von 6-Methylamino-2-methylheptansalicylat von beliebiger Konzentration dadurch hergestellt weiden können, daß man Dimethylaminophenyldimethylpyrazolon-Calciumsalicylat und zusätzlich noch mindestens so viel Dimethylaminophenyldimethylpyrazo-Ion zusetzt, als dem molekularen Verhältnis Heptansalicylat : Pyrazolon wie i : i entspricht. Diese Lösungen entsprechen durch ihren hohen Gehalt an Pyrazolon den Erfordernissen der Therapie für ein gut wirkendes Analgetikum; sie eignen sich in gleich hervorragender Weise zur Verabreichung per os und als Injektion.It has now been found that solutions of 6-methylamino-2-methylheptane salicylate which remain clear of any concentration produced by using dimethylaminophenyldimethylpyrazolone calcium salicylate and in addition at least as much dimethylaminophenyldimethylpyrazo-ion added, than corresponds to the molecular ratio of heptane salicylate: pyrazolone as i: i. These solutions meet the requirements due to their high pyrazolone content the therapy for a well-working analgesic; they are equally excellent Way of administration orally and as an injection.

In Ausübung des Verfahrens kann man einerseits fertiges Nlethylaminomethylheptansalicylat oder Base, und Säure im stöchiometrischen Mengenverhältnis, andererseits fertiges Dimethylaminophetiyldimethylpyrazolon-Calciumsalicylat oder dessen Komponenten, Pyrazolon bzw. Pyrazolonsalicylat, Calciumoxyd, -hydroxyd oder -carbonat und Salicylsäure, in den berechneten Mengen anwenden. Man kann den Lösungen gewünschtenfalls noch andere neutral reagierende Arzneimittel, wie z. B. Coffeincalciumsalicylat, zusetzen,ohne die Haltbarkeit der Lösungen zti beeinträchtigen.In the practice of the process, on the one hand, finished methylaminomethylheptane salicylate can be used or base, and acid in stoichiometric proportions, on the other hand finished Dimethylaminophetiyldimethylpyrazolone calcium salicylate or its components, Pyrazolone or pyrazolone salicylate, calcium oxide, hydroxide or carbonate and salicylic acid, apply in the calculated quantities. You can still use the solutions if you want other medications with a neutral reaction, such as B. caffeine calcium salicylate, add without affect the shelf life of the solutions.

Beispiel i Man erhält bei 20° einheitliche und haltbare Lösungen von Methylaminomethylheptansalicylat bei folgenden Ansätzen der 3 Komponenten: liethylamino- Dimethylamino- Dimethylamino- methylheptan- phenyldimethyl- phenyldimethyl- Wasser salicylat pyrazolon- pyrazolon Calciumsalicylat io g 2o g 8,2 g 61,8 g oder 2o g 2o g 16,4 9 4369 oder 25 g 2o g 20,5 g 34,59 An Stelle von 20 g DimethyIaminophenyldimethylpyrazolon-Calciumsalicylat können auch ii,9i g Pyrazolon und 9,o2 g Calciumsalicylat - 2 H20 angewandt werden. Hierbei ist gelindes Erwärmen der Mischung nötig.Example i At 20 °, solutions of methylaminomethylheptane salicylate which are uniform and stable are obtained with the following batches of the 3 components: liethylamino- dimethylamino- dimethylamino- methylheptane-phenyldimethyl-phenyldimethyl-water salicylate pyrazolone pyrazolone Calcium salicylate io g 2o g 8.2 g 61.8 g or 2o g 2o g 16.4 9 4369 or 25 g 2o g 20.5 g 34.59 Instead of 20 g of dimethylaminophenyldimethylpyrazolone calcium salicylate, 1.91 g of pyrazolone and 9.02 g of calcium salicylate - 2 H20 can also be used. Gentle warming of the mixture is necessary.

Beispiel 2 Bei 2o° werden einheitliche und haltbare Lösungen von Methylaminomethylheptansalicylat bei folgenden Ansätzen erhalten: Methylamino- Dimethylamino- Dimethylamino- methylheptan- phenyldimethyi- phenyldimethyl- Wasser salicylat pymzolon- pyrazolon Calciumsalicylat io g io g 12,i g 67,99 io g 2o g 11,6 g 58,49 io g 309 11,o g 49,09 Beispiel 3 Eine bei 2o° einheitliche und haltbare Lösung von Methylaminomethylheptansalicylat wird erhalten durch Lösen von 6j79 Methylaminomethylheptansalicylat, 22,5 g Dimethylaminophenyldimethylpyrazolon-Calciumsalicylat, 5,o8g Dimethylaminophenyldimethylpyrazolon und 11,25 g Coffeincalciumsalicylat in 55 ccm Wasser.Example 2 At 20 °, uniform and stable solutions of methylaminomethylheptane salicylate are obtained in the following approaches: Methylamino dimethylamino dimethylamino methylheptanephenyldimethyiphenyldimethyl water salicylate pymzolone pyrazolone Calcium salicylate io g io g 12, ig 67.99 io g 2o g 11.6 g 58.49 io g 309 11, above 49.09 EXAMPLE 3 A solution of methylaminomethylheptane salicylate which is uniform and stable at 20 ° is obtained by dissolving 679 methylaminomethylheptane salicylate, 22.5 g of dimethylaminophenyldimethylpyrazolone calcium salicylate, 5, o8 g of dimethylaminophenyldimethylpyrazolone and 11.25 g of caffeine in 55 g of caffeine.

Claims (2)

PATENTANSPRÜCHE: 1. Verfahren zur Herstellung von konzentricrten wäßrigen Lösungen des 6-Methylamino-2-methylheptansalicylats, dadurch gekennzeichnet, daß man Dimethylaminophenyldimethylpyrazolon-Calciumsalicylat und zusätzlich mindestens so viel Dimethylaminophenyldimethylpyrazolon als Lösungsvermittler verwendet, als dem molekularen Verhältnis 6-Methylamino-2-methylheptansalicylat : Dimethylaminophenyldimethylpyrazolon wie i : i entspricht. PATENT CLAIMS: 1. A process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate, characterized in that dimethylaminophenyldimethylpyrazolone calcium salicylate and additionally at least as much dimethylaminophenyldimethylpyrazolone as a solubilizer as the 6-methylheptane-alicylate molecular ratio is used as a solubilizer. Dimethylaminophenyldimethylpyrazolon as i: i corresponds to. 2. Verfahren nach Anspruch i, dadurch gekennzeichnet, daß man an Stelle von Dimethylaminophenyldimethylpyrazolon-Calciumsalicy lat dessen Komponenten Dimethylaminophenyldimethylpyrazolon einerseits und Calciumoxyd, -hydroxy d oder -carbonat sowie Salicylsäure andererseits oder Dimethylaminophenyldimethylpyrazolonsalicylat und Calciumoxyd, -hvdroxyd oder -carbonat verwendet.2. The method according to claim i, characterized in that instead of dimethylaminophenyldimethylpyrazolone calcium salicy lat of it Components Dimethylaminophenyldimethylpyrazolon on the one hand and calcium oxide, -hydroxy d or carbonate and salicylic acid on the other hand or dimethylaminophenyldimethylpyrazolone salicylate and calcium oxide, hydroxide or carbonate is used.
DEK1647A 1950-02-05 1950-02-05 Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect Expired DE835928C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEK1647A DE835928C (en) 1950-02-05 1950-02-05 Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEK1647A DE835928C (en) 1950-02-05 1950-02-05 Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect

Publications (1)

Publication Number Publication Date
DE835928C true DE835928C (en) 1952-04-07

Family

ID=7209021

Family Applications (1)

Application Number Title Priority Date Filing Date
DEK1647A Expired DE835928C (en) 1950-02-05 1950-02-05 Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect

Country Status (1)

Country Link
DE (1) DE835928C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE948184C (en) * 1953-01-31 1956-08-30 Hoechst Ag Process for the production of aqueous solutions of steroid hormones

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE948184C (en) * 1953-01-31 1956-08-30 Hoechst Ag Process for the production of aqueous solutions of steroid hormones

Similar Documents

Publication Publication Date Title
DE3314150A1 (en) DENTAL CEMENT
DE1467858A1 (en) Process for the production of non-hygroscopic, water-dispersible, pharmaceutical preparations
DE835928C (en) Process for the preparation of concentrated aqueous solutions of 6-methylamino-2-methylheptane salicylate with an analgesic effect
DE2341742A1 (en) NEW PHARMACEUTICAL AGENTS BASED ON ANTIBIOTICS AND PYRROLIDONE CARBONIC ACID OR ITS DERIVATIVES
DE630326C (en) Process for the preparation of double compounds of calcium or strontium with theobromine or theophylline and an organic acid
DE2342214C3 (en) Remedies
DE805769C (en) Process for the preparation of injectable solutions of guaiacol
DE663512C (en) Process for increasing the solubility of salicylic acid in fats or fatty oils
DE2635293A1 (en) SALT MIXTURE, IN PARTICULAR EASILY ASSIMILABLE MEDICINAL MIXTURE WITH INCREASED SOLUBILITY, CONTAINS CALCIUM SALTS AND / OR MAGNESIUM SALTS
DE904652C (en) Process for the production of concentrated, durable aqueous solutions of furanochromones
DE942534C (en) Process for the production of durable and highly effective solutions or suspensions of antibiotic agents
DE652876C (en) Process for the production of durable solutions of p-aminobenzoyldiaethylaminoethanol
AT149825B (en) Process for the production of alkali or alkaline earth double compounds of dimethylxanthines with organic acids.
DE469788C (en) Process for the preparation of durable calcium-containing solutions of theophylline suitable for injection purposes
DE399903C (en) Process for the preparation of salts of dymethylxanthines with organic acids
DE2158730C3 (en) Process for producing a calcium salt with high solubility
DE1030515B (en) Process for the production of stable injectable solutions of an easily water-soluble magnesium double salt of ascorbic acid and salicylic acid
DE695034C (en) Process for the preparation of durable solutions of p-aminobenzenesulfonamide
DE431847C (en) Process for the production of intravenous injectable preparations against bilharzia
DE1227191B (en) Process for the production of liquid lecithin preparations
DE418485C (en) Process for the manufacture of preparations which, when heated or dissolved in water, cause carbonic acid to split off
DE922298C (en) Process for the production of stable aqueous injection solutions of 2-methyl-5, 8-dimethoxy-furanochromone
DE714141C (en) Process for the production of long-lasting, saturated solutions of calcium glucoheptonate
AT142713B (en) Process for the production of preparations which can be kept in solution and which contain anesthetizing and vasoconstricting agents.
DE543380C (en) Process for the production of disinfectants